<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03099824</url>
  </required_header>
  <id_info>
    <org_study_id>GTO-003</org_study_id>
    <nct_id>NCT03099824</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of the Safety and Pharmacokinetics of GC4711 (Oral Capsule) Compared to GC4419 (IV Infusion) and GC4711 (IV Infusion) in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Open-label Study to Compare the Safety and Pharmacokinetics of Various Formulations of Orally Administered Superoxide Dismutase Mimetic GC4711 With Intravenously Administered Superoxide Dismutase Mimetic GC4419 or GC4711 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galera Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galera Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the phase 1, GTO-003 clinical study is to determine the safety and
      pharmacokinetics of a single dose of a new drug called GC4711 when given as an oral capsule.
      This study will compare capsules of GC4711 when given orally to a similar drug, GC4419, or
      GC4711 when either is given as an intravenous infusion.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events and Laboratory Abnormalities</measure>
    <time_frame>From randomization through study completion (estimated up to 13 days)</time_frame>
    <description>Number of Participants With Treatment-Emergent Adverse Events and/or Laboratory Abnormalities.</description>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>GC4419 IV + GC4711 Oral G-101 (82mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GC4419 IV + GC4711 Oral G-101 (164mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GC4419 IV + GC4711 Oral G-101 (246mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GC4419 IV + GC4711 Oral G-111 (175mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GC4419 IV + GC4711 Oral G-112 (145mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GC4711 IV + GC4711 Oral G-119 (233mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GC4711 IV + GC4711 Oral G-125 (233mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC4711 Oral Capsule G-101</intervention_name>
    <description>82 mg (1 capsule)</description>
    <arm_group_label>GC4419 IV + GC4711 Oral G-101 (82mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV GC4419</intervention_name>
    <description>GC4419 will be infused IV as a single dose of 27 mg in 247 mL normal saline, totaling 250 mL, over a 60-minute period using a programmable pump.</description>
    <arm_group_label>GC4419 IV + GC4711 Oral G-101 (164mg)</arm_group_label>
    <arm_group_label>GC4419 IV + GC4711 Oral G-101 (246mg)</arm_group_label>
    <arm_group_label>GC4419 IV + GC4711 Oral G-101 (82mg)</arm_group_label>
    <arm_group_label>GC4419 IV + GC4711 Oral G-111 (175mg)</arm_group_label>
    <arm_group_label>GC4419 IV + GC4711 Oral G-112 (145mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC4711 Oral Capsule G-101</intervention_name>
    <description>164 mg (2 capsules)</description>
    <arm_group_label>GC4419 IV + GC4711 Oral G-101 (164mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC4711 Oral Capsule G-101</intervention_name>
    <description>246 mg (3 capsules)</description>
    <arm_group_label>GC4419 IV + GC4711 Oral G-101 (246mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC4711 Oral Capsule G-111</intervention_name>
    <description>175 mg (1 capsule)</description>
    <arm_group_label>GC4419 IV + GC4711 Oral G-111 (175mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC4711 Oral Capsule G-112</intervention_name>
    <description>145 mg (1 capsule)</description>
    <arm_group_label>GC4419 IV + GC4711 Oral G-112 (145mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC4711 Oral Capsule G-119</intervention_name>
    <description>233 mg (1 capsule)</description>
    <arm_group_label>GC4711 IV + GC4711 Oral G-119 (233mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC4711 Oral Capsule G-125</intervention_name>
    <description>233 mg (1 capsule)</description>
    <arm_group_label>GC4711 IV + GC4711 Oral G-125 (233mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV GC4711</intervention_name>
    <description>GC4711 will be infused IV as a single dose of 30 mg in 250 mL normal saline, totaling 251 mL, over a 60-minute period using a programmable pump.</description>
    <arm_group_label>GC4711 IV + GC4711 Oral G-119 (233mg)</arm_group_label>
    <arm_group_label>GC4711 IV + GC4711 Oral G-125 (233mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy men and women between 18 and 50 years (inclusive) of age;

          2. Subjects who provide written informed consent

          3. Body Mass Index (BMI) 18 to 32 kg/m2 (inclusive) and weighing at least 50 kg during
             Screening and at Baseline. Every effort will be made to enroll across BMI range to
             evaluate relation between dose and weight;

          4. Subjects in general good health in the investigator's opinion

          5. Chest X-ray free of clinically significant abnormalities

          6. Blood pressure and heart rate within normal limits

          7. Female subjects must:

               1. Have a negative serum pregnancy test during Screening and a negative urine
                  pregnancy test at Baseline, and be willing and able to use a medically acceptable
                  method of birth control or be postmenopausal.

               2. Be non-lactating

               3. Be at least two years postmenopausal, surgically sterile or practicing effective
                  contraception

        Exclusion Criteria:

          1. History of clinically significant illness, medical condition, or laboratory
             abnormality within three months

          2. History of any clinically significant cardiovascular, hepatic, renal, or
             gastrointestinal abnormality;

          3. History of hypotension

          4. Known contraindication, hypersensitivity and/or allergy to investigational products

          5. Use of any prescription or over-the-counter medication within one week prior to
             baseline;

          6. Anticipated need for any medication during the course of the study

          7. Use of nitrates or erectile dysfunction drugs such as phosphodiesterase type 5 (PDE 5)
             inhibitors (e.g., sildenafil, tadalafil, or similar agents), from 24 hours prior to
             screening throughout participation in the study;

          8. Use of or other drugs that may, in the judgment of the treating investigator, create a
             risk for a precipitous decrease in blood pressure

          9. Presence of orthostatic hypotension at screening or baseline

         10. Use of any vitamin or mineral supplement 24 hours prior to dosing, or anticipated use
             of any vitamin or mineral supplement throughout the duration of the study;

         11. Positive HIV, Hepatitis B or Hepatitis C serology at Screening;

         12. Known history of substance abuse, drug addiction, or alcoholism within 3 years

         13. Anticipated inability to abstain from alcohol, tobacco, or caffeine use from 48 hours
             prior to the administration of study drug and throughout the duration of the study;

         14. Positive drug and alcohol toxicology screens during Screening and at Baseline;

         15. History of smoking or any use of a tobacco product within six months prior to
             Baseline;

         16. Donation of blood or blood products within 30 days prior to the Baseline and through
             duration of study;

         17. Mentally unstable or incapable of being compliant with the protocol

         18. Receipt of an investigational test substance within three months prior to the first
             dose of investigational products (GC4419, GC4711, or placebo), or anticipated
             receiving any investigational products (including placebo on another investigational
             study) other than GC4711 and GC4419 during the course of this study;

         19. Subject has previously participated in this study, or in a prior study of GC4419,
             GC4711 or GC4702.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon T Holmlund, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Chief Medical Officer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kara T Terry, MD</last_name>
    <phone>(610)725-1500</phone>
    <email>kterry@galeratx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nucleus Network</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kara Terry</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 20, 2017</study_first_submitted>
  <study_first_submitted_qc>March 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <last_update_submitted>September 18, 2019</last_update_submitted>
  <last_update_submitted_qc>September 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

